Taysha Gene Therapies to share TSHA-102 gene therapy advancements at CNSAM event

Taysha Gene Therapies to share TSHA-102 gene therapy advancements at CNSAM event
Taysha shares gene therapy update

Taysha Gene Therapies announced plans to share updates on its TSHA-102 gene therapy program, which is currently in clinical evaluation, at the Child Neurology Society Annual Meeting (CNSAM).

The company highlighted its ongoing collaboration with the scientific and clinical community as it supports efforts to advance child neurology. Detailed company progress or results related to TSHA-102 were not provided in the announcement.

Taysha previously featured multiple encore presentations on TSHA-102 for Rett syndrome at a key neurology meeting, according to an earlier company announcement. The TSHA-102 program remains in clinical evaluation for neurological indications. The latest update follows ongoing efforts to engage with the child neurology research community.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.